Anti-China bills portend massive blow to biotech: BioCentury survey

Brace for impact. Legislation targeting Chinese CDMOs and genomics companies that is making its way through Congress, if passed in its current form, will deal a massive blow to biotech companies, with consequences likely to be felt not only throughout the ecosystem, but also by patients. The responses to BioCentury’s survey signal deep concern, primarily for the ability to replace manufacturing capacity, with views split on the wisdom and rationale of the legislation’s goals per se.

BIO’s stance on the legislation, which it reversed last week to support the Biosecure Act, also has the community divided. Twice as many oppose the trade organization’s new position as agree with it, and many believe the organization has not explained its reasoning. ...